Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Exelixis Inc. (EXEL), South San Francisco, Calif. Product: XL184 Business: Cancer Molecular target: Vascular
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury